



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/989,727	11/19/2001	Avi J. Ashkenazi	P2730P1C65	2390

35489 7590 12/23/2005

HELLER EHRMAN LLP  
275 MIDDLEFIELD ROAD  
MENLO PARK, CA 94025-3506

EXAMINER

ROMEO, DAVID S

ART UNIT PAPER NUMBER

1647

DATE MAILED: 12/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



### DETAILED ACTION

The amendment filed 09/30/2005 has been entered. Claims 124–126, 129 and 135–138 are pending and being examined.

#### **Maintained Formal Matters, Objections, and/or Rejections:**

##### 5 ***Claim Rejections - 35 USC § 102***

Claims 124–126, 129, 135 and 137 are rejected under 35 U.S.C. 102(f) because the applicant did not invent the claimed subject matter.

Applicants refer to a declaration of Dr. William Wood. The declaration of Dr. William Wood filed 09/30/2005 is insufficient to overcome the rejection of claims 124–126, 129, 135 and  
10 137 based upon 35 U.S.C. 102(f) because the applicant did not invent the claimed subject matter as set forth in the last Office action because: declarant states that Exhibit A is attached and forms part of the declaration. Declarant argues that Incyte EST3476792 sequence did not encode for a full-length polypeptide because the Incyte sequence truncated before the nucleotides encoding for the stop codon of the polypeptide. Declarant's arguments have been fully  
15 considered but they are not persuasive. Firstly, Exhibit A was not attached and did not form part of the declaration. Secondly, Declarant refers to the Incyte "sequence." A DNA "sequence" is merely descriptive of the linear order of monomers of which a DNA molecule is made and is not a DNA molecule. In Example 118 the specification states:

20 ... the Incyte EST clone 3476792 was purchased and the cDNA insert was obtained and sequenced. It was found that this insert encoded a full-length protein. The sequence of this cDNA insert is shown in FIG. 265 and is herein designated as DNA60621-1516.

From the evidence provided it cannot be determined if the "sequence" referred to by declarant is a partial sequence of the cDNA insert or if it is the complete and entire sequence of the cDNA

Art Unit: 1647

insert in the purchased clone. Therefore, it is appropriate to maintain the rejection. Applicants' base their arguments on the declaration of Dr. Wood. Applicant's arguments have been fully considered but they are not persuasive because the declaration of Dr. Wood insufficient to overcome the rejection.

5

### ***Double Patenting***

Claims 124–126, 129 and 135–138 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 13-25 of copending Application No. 10/692,299. Applicants' request to hold this rejection in abeyance is acknowledged. However, there are no provisions for holding a rejection in abeyance.

10

### ***Conclusion***

No claims are allowable.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1647

FRIDAY FROM 7:30 A.M. TO 4:00 P.M. IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, BRENDA BRUMBACK, CAN BE REACHED ON (571) 272-0961.

IF SUBMITTING OFFICIAL CORRESPONDENCE BY FAX, APPLICANTS ARE ENCOURAGED TO SUBMIT OFFICIAL CORRESPONDENCE TO THE CENTRAL FAX NUMBER FOR OFFICIAL CORRESPONDENCE, WHICH IS (571) 273-8300.

CUSTOMERS ARE ALSO ADVISED TO USE CERTIFICATE OF FACSIMILE PROCEDURES WHEN SUBMITTING A REPLY TO A NON-FINAL OR FINAL OFFICE ACTION BY FACSIMILE (SEE 37 CFR 1.6 AND 1.8).

ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.



DAVID ROMEO  
PRIMARY EXAMINER  
ART UNIT 1647

DSR  
DECEMBER 20, 2005